Your session is about to expire
← Back to Search
Other
C-KAD Ophthalmic Solution for Asteroid Hyalosis
Phase 2
Waitlist Available
Research Sponsored by Chakshu Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Presence of asteroid hyalosis
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180
Awards & highlights
Study Summary
To determine the safety and initial efficacy of C-KAD ophthalmic solution in patients with asteroid hyalosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 180
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Reduction in the number of asteroid bodies
Side effects data
From 2015 Phase 4 trial • 157 Patients • NCT020033916%
Ocular hyperaemia
5%
Eye pruritus
2%
Nasopharyngitis
2%
Dry eye
1%
Acute tonsillitis
1%
Pharyngitis
1%
Conjunctivitis allergic
1%
Eyelids pruritus
1%
Blepharal pigmentation
1%
Eye irritation
1%
Cataract
1%
Arthritis
1%
Hypersensitivity
1%
Eye pain
1%
Ocular surface disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
DuoTrav
Beta-blocker
Trial Design
1Treatment groups
Experimental Treatment
Group I: C-KAD Ophthalmic SolutionExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
C-KAD Ophthalmic Solution
2007
N/A
~20
Find a Location
Who is running the clinical trial?
Chakshu Research, Inc.Lead Sponsor
3 Previous Clinical Trials
173 Total Patients Enrolled
Ira Wong, MDStudy DirectorChakshu Research, Inc.
2 Previous Clinical Trials
92 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger